Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02736188 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)
A Phase 3 study, sponsored by Ultragenyx Pharmaceutical.
- Terminated
- Registry status
- Phase 3
- Development phase
- 143
- Enrollment target
NCT02736188 is a Phase 3 study that was terminated before completion, run by Ultragenyx Pharmaceutical. The registered enrollment target is 143 participants.
The verdict
NCT02736188, a Phase 3 study, was terminated before completion, sponsored by Ultragenyx Pharmaceutical.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 143 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the long-term safety and efficacy of Ace-ER treatment in subjects with GNEM.
Interventions
- DRUG Aceneuramic Acid Extended-Release Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2016-05-02 |
| Est. Completion | 2018-01-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02736188
The ClinicalTrials.gov registry entry for NCT02736188 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ultragenyx Pharmaceutical, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aceneuramic Acid Extended-Release Tablets is the first listed.
NCT02736188 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02736188 about?
NCT02736188 is a clinical study titled "Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)". The objective of this study is to evaluate the long-term safety and efficacy of Ace-ER treatment in subjects with GNEM.
What is the current status of trial NCT02736188?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 143 participants. The study started on 2016-05-02. Estimated completion is 2018-01-10.
What interventions are being tested in trial NCT02736188?
The interventions under investigation include: Aceneuramic Acid Extended-Release Tablets (DRUG).
Who is sponsoring clinical trial NCT02736188?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.